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Purpose: This study aims to screen microRNAs (miRNAs), for an early diagnosis of colorec-
tal cancer, by deep sequencing and evaluation of total miRNAs using clinical samples from a 
Chinese patient population.
Methods: Total small RNAs from normal colonic mucosa, colonic adenomas, and colorectal 
cancer tissues were prepared for miRNA analysis by deep sequencing. The sequencing data 
were then analyzed by bioinformatics for candidate diagnostic miRNAs, which were further 
validated for their up- or downregulation status.
Results: Comparison of cancer tissues with normal mucosa identified 99 upregulated and 90 
downregulated miRNAs. Comparison of adenomas and normal mucosa found 114 upregu-
lated and 107 downregulated miRNAs. Comparison of cancer and adenoma tissues found 70 
upregulated and 27 downregulated miRNAs. Selected up- and downregulated miRNAs were 
validated for their expressions in 12 cases of patients with cancer and polyps. Specifically, for the 
upregulated miRNAs, miR-18a-5p and miR-21-3p were significantly upregulated in adenomas 
and cancer tissues, compared with the normal mucosa; miR-135b-5p, miR-17-5p, miR-182-5p, 
miR-200a-5p, and miR-200c-3p were significantly upregulated in cancer tissues compared to the 
normal mucosa, but their differential expression was not significant in adenoma tissues when 
compared with the normal mucosa. miR-183-5p and miR-96-5p were significantly upregulated in 
adenoma tissues when compared with normal mucosa, but these differences were not significant in 
cancer tissues when compared to normal mucosa. For the downregulated miRNAs, miR-133a-3p 
was significantly downregulated in both adenoma and cancer tissues when compared to normal 
mucosa; miR-204-5p, miR-125b-5p, miR-139-5p, miR-100-5p, and miR-30a-5p were signifi-
cantly downregulated in cancer tissues compared to the normal mucosa, but their differential 
expression was not significant in adenoma tissue compared to normal mucosa.
Conclusion: The findings of this study show that a number of miRNAs might be important 
in the diagnosis and prognosis of colorectal cancer in Chinese patients using the method of 
small RNA deep sequencing. Upregulation of miR-18a-5p and miR-21-3p or downregulation 
of miR-133a-3p in adenoma and cancer tissues may serve as an index for early screening of 
colorectal cancer. Other miRNAs, such as miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, 
miR-200c-3p, miR-183-5p, and miR-96-5p, which were either up- or downregulated, in cancer 
tissues, but not in adenoma tissues, have limited significance in early diagnosis. Further study 
is needed to determine a screening index with diagnostic value.
Keywords: colorectal cancer, colorectal adenoma, miRNA, deep sequencing
Introduction
Colorectal cancer accounts for one third of cancer-related deaths worldwide and 
this trend is still increasing. Although application of comprehensive treatments, 
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including surgery, has achieved a significant improvement 
in the 5-year survival rate, the overall estimated death rate is 
still ~50%-60%.1 Early diagnosis is thus an effective way to 
prolong life of patients with colorectal cancer.
The term micro-RNA (miRNA) refers to a type of small 
RNA of length 19–22 nucleotides in vivo. After a series 
of reactions, it finally forms an RNA-induced silencing 
complex. The miRNA-associated RNA-induced silencing 
complex binds to its target messenger RNA (mRNA) at 
the 3′-untranslated region, so that it can cleave and degrade 
the target mRNA or inhibit further translation of the target 
mRNA, leading to a loss of function of the target gene.
miRNA plays an important role in the occurrence and 
development of colorectal cancer. miRNA affects many 
known oncogenes and antioncogenes and is involved in 
the regulation of the signal transduction pathway related 
to colorectal cancer. Thus, miRNAs, many of which have 
differential expression profiles, may be used to serve as 
biological markers for predicting the development of and 
prognosis of colorectal cancer.2,3
In recent years, changes of miRNA levels in the human 
circulation have gained more attention for their role in 
the early diagnosis of colorectal cancer.3–5 Luo et al3 used 
TaqMan miRNA slugs in 50 cases of colorectal cancer and 
50 cases of adenoma and found nine miRNAs that had dif-
ferential expression in colorectal cancer when compared to 
normal mucosa. They hypothesized that assay of these nine 
markers can contribute to the early diagnosis of colorectal 
cancer. Ng et al4 assayed 90 known miRNAs in 90 cases 
of colorectal cancer, 20 cases of gastric cancer, 20 cases of 
inflammatory bowel disease, and 50 healthy people. Their 
findings showed that miR-17-3p and miR-92 were increased 
in patient blood, and further verification showed that, among 
the 180 cases, miR-92 had a distinct increase in patient 
blood. In contrast to the report by Ng et al,4 Faltejskova et 
al,6 by repeating the research performed by Ng et al4 among 
Czech patients, found that the levels of miR-17-3p (P=0.18), 
miR-29a (P=0.14), and miR-92a (P=0.60) had no significant 
difference in colorectal cancer when compared to a control 
group. The differences in findings might have been due to the 
distinct sources of samples, including the regional environ-
ment distinction of patient samples.
The colorectal cancer screen using miRNAs was claimed 
to have sensitivity of 89% and specificity of 70%. Research 
reported by Huang et al5 found that using miR-29a and miR-
92a as biomarkers for early diagnosis had 83% sensitivity 
and 84.7% specificity for colorectal cancer diagnosis and 
77% sensitivity and 79.7% of specificity for colorectal 
polyps.
Although previous studies showed valuable data on 
miRNAs as potential biomarkers in colorectal cancer, results 
were still limited and were sometimes contradictory with 
each other due to different sources of samples.3–5 Cancer-
stage-related miRNAs as valuable biomarkers are still lack-
ing. In this study, controlled experiments were performed 
on colorectal cancer with its distinct developmental stages, 
including colorectal polyps, and on normal mucosa. miRNA 
deep sequencing was performed on cancer and precancer 
tissues of all stages, to determine simultaneous variations in 
the miRNA index for colorectal cancer and colorectal polyps. 
This index can be used in further studies to confirm its value 
in the early diagnosis of colorectal cancer.
Materials and methods
clinical specimens
The specimens used for the deep sequencing were from four 
typical patients who had undergone surgery or endoscopy 
at the National Center of Colorectal Surgery, the Third 
Affiliated Hospital of Nanjing University of Traditional 
Chinese Medicine. One case was a 52-year-old female, a 
patient with colorectal cancer (T2N0M0) who had anterior 
resection operation; the cancer tissue and normal mucosa 
were taken for study. Another case was a 50-year-old male 
with sigmoid cancer with a colon polyp (T3N0M0), who 
had received a sigmoidectomy operation for sigmoid cancer 
and endoscopic polypectomy for colon adenoma; the cancer, 
adenoma, and normal mucosa tissues were taken for study. A 
third case was a patient with polyps in the cecum and cancer 
of the horizontal colon (T3N1M0); a right hemicolectomy 
surgery was performed; his cancer, adenoma, and normal 
mucosa tissues were obtained for study. A fourth case had 
a polyp of the sigmoid colon; endoscopic mucosal resec-
tion was performed and specimens were taken for study. In 
total, there were three samples each of cancer, adenoma, and 
normal mucosa tissues. All samples were preserved in liquid 
nitrogen. The study was approved by the Ethics Committee 
of The Third Affiliated Hospital of Nanjing, University of 
Traditional Chinese Medicine, and all patients provided 
written informed consent.
mirna deep sequencing
We implemented miRNA deep sequencing with the method 
published by Schee et al7 and carried out high-throughput 
sequencing on the specimens using the 50 bp single-end 
sequencing model on an Illumina HiSeq2500 (Illumina, San 
Diego, CA, USA) sequencing platform. Frozen specimens 
were used with the Sangong kit (Sangong Biotechnology, 
Shanghai, People’s Republic of China) for total RNA 
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extraction. The total RNA was quantified with NanoDrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA), and 500 ng of total RNA was visualized on 
1% agarose gel after electrophoresis. A miRNA library was 
established with the TruSeq® miRNA Sample Prep Kit v2 
(Illumina Company), with reverse transcriptase polymerase 
chain reaction (RT-PCR) to enrich the library and with Qubit 
kit (Thermo Fisher Scientific) to quantify miRNA libraries. 
Sequencing was performed with the HiSeq2500. The data 
were transformed into the FASTQ format for expression and 
differential profile analysis. The results were subjected to 
cluster analysis with Illumina’s software packages (SCS2.9/
RTA1.9 and Off-line Basecaller v1.9). miRNAs that were 
differentially expressed, either increased or decreased, in 
colorectal cancer and colorectal adenoma samples were 
selected for the analysis.
Quantitative RT-PCR test and verification 
of mirna deep-sequencing results
Twelve colorectal cancer tissues as well as normal mucosa 
(.10 cm away from the cancer) and 12 samples of colonic 
adenoma were used for quantitative RT-PCR (qRT-PCR) 
validation of the differentially expressed miRNAs revealed 
by the deep sequencing. The RNA samples were derived from 
patients with colorectal cancer; seven were males and five 
were females, with ages ranging from 35 years to 75 years 
and a median age of 65 years. These included six cases of 
colorectal cancer, four cases of sigmoid cancer, and two cases 
of ascending colon cancer. Additional validations were con-
ducted by using RNA samples from 12 patients with colorectal 
adenomas, eight males and four females with ages ranging 
from 40 years to 73 years and a median age of 62 years. These 
included seven cases of rectal polyps, four cases of sigmoid 
colon polyps, and one case of ascending colon polyps.
We designed reverse transcription stem–loop primer and 
specificity amplification primers, and the RNU6 qRT-PCR 
was used as an internal reference for miRNA quantification. 
The average Ct value of three replicates was calculated for 
each sample. The Ct values of the internal reference were also 
obtained three times and used for sample value corrections. 
The corrected Ct values were directly plotted for differential 
expression analysis. Please note that the samples were not 
paired in experiments, and therefore their Ct values were unfit 
for the calculation of 2-ΔΔCt (cannot appropriately subtract 
the Ct value of one sample as a control group). Therefore, 
direct plotting of the Ct value, which was subtracted from 
the expression of the internal reference of normal, adenoma, 
and cancer tissues, was used for their expressions. One-
way analysis of variance in a normal distribution and the 
Mann–Whitney U-test equivalent, an inspection method 
for nonnormal distribution or variance, were used to test all 
groups studied.
Results
Differential expression of mirnas 
in different developmental stages of 
colorectal cancerous tissues
To analyze the differential expression of miRNAs in dif-
ferent stages of colorectal cancerous tissues, miRNAs 
with two-fold changes were compared for their expres-
sion patterns among adenoma, cancer, and normal mucosa 
(P#0.05, expression quantity with two-fold changes). 
We conducted the following comparisons (Figure 1 and 
Table 1): 1) between cancerous tissue and normal mucosa 
tissue; 2) between adenoma and normal mucosa; and 3) 
between cancer and adenoma. Our data analysis showed 
that 99 miRNAs were upregulated and 90 miRNAs were 
downregulated in cancers relative to normal mucosa. 
Furthermore, 114 miRNAs were found to be upregulated 
and 107 downregulated in adenoma compared with normal 
mucosa. Seventy miRNAs were upregulated and 27 down-
regulated in cancers relative to adenoma miRNAs. Among 
all the upregulated miRNAs, 32 miRNAs were simultane-
ously upregulated in both cancer and adenoma, and nine had 
significantly differential expression between adenoma and 
cancer. Among all the downregulated miRNAs, 27 miRNAs 
were simultaneously decreased in both adenoma and cancer, 
and only two had significant differential expression between 
adenoma and cancer. Nine miRNAs, increased or decreased 
in both colorectal cancer and colorectal adenomas, were 
chosen for further validation.
Validation of the differentially expressed 
mirnas in colorectal cancer tissues of 
patients
To verify the reliability of the deep-sequencing data, we 
picked 12 miRNAs that were found to be differentially 
expressed by deep sequencing. The validation was conducted 
using more samples of a Chinese patient population, and the 
data are shown in Figures 2 and 3.
For the upregulated miRNAs (Figure 2), miR-18a-5p and 
miR-21-3p were statistically significantly increased in both 
adenoma and cancer tissues, compared to the normal mucosa. 
miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, and 
miR-200c-3p were significantly upregulated in cancer com-
pared with the normal mucosa tissues but not significantly 
in adenoma relative to normal mucosa tissues. miR-183-5p 
and miR-96-5p were significantly upregulated in adenoma 
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compared with normal mucosa tissues but showed no dif-
ferential expression between cancer and normal mucosa.
For the downregulated miRNA (Figure 3), only miR-
133a-3p was significantly downregulated in both adenoma 
and cancer tissues when compared with normal mucosa. 
miR-204-5p, miR-125b-5p, miR-139-5p, miR-100-5p, and 
miR-30a-5p were significantly downregulated in cancer 
relative to normal mucosa but not significantly in adenoma 
compared with normal mucosa tissues. Among these down-
regulated miRNAs, no miRNA showed any differential 
expression either between adenoma and cancer tissues or 
between cancer and normal mucosa tissues. The statistical 
results are shown in Table 2.
Discussion
The use of molecular biomarkers for the early diagnosis of 
colorectal cancer is an important topic of current research.2–4 
Recent studies have found that miRNA plays an important 
role in the pathogenesis and development of colorectal 
cancer.2–4 The use of the characteristics of miRNAs, which 
can be detected at early stages in the blood circulation system, 
for early diagnosis of cancers has achieved very promising 
results.4–7 However, due to miRNA expression variations 
among different races, environments, diet styles, and so on, 
the results of the detected miRNA expressions may be differ-
ent. In this study, small RNA deep-sequencing experiments 
were specifically conducted on samples of patients with 
Table 1 mirna markers were both upregulated and downregu-
lated in both adenoma and cancer tissues
Upregulated miRNA in  
both adenoma and cancer
Downregulated miRNA in 
both adenoma and cancer
hsa-mir-29b-3p hsa-mir-135a-5p
hsa-mir-362-5p hsa-mir-9-5p
hsa-mir-182-5p hsa-mir-129-5p
chr7_9113 hsa-mir-204-5p
hsa-mir-584-5p chr20_19299
chrX_21021 chr9_10749
hsa-mir-1268b hsa-mir-3195
hsa-mir-552-3p hsa-mir-145-5p
hsa-mir-21-3p hsa-mir-133a-3p
hsa-mir-96-5p hsa-mir-195-3p
hsa-mir-17-5p hsa-mir-328-3p
hsa-mir-20a-5p hsa-mir-30c-2-3p
chr21_19839 hsa-mir-139-5p
chr7_9117 hsa-mir-504-5p
hsa-mir-3182 chr17_17056
hsa-mir-27a-5p chr19_18516
hsa-mir-183-5p chr4_5126
hsa-mir-548d-5p chr17_17055
hsa-mir-18a-5p hsa-mir-30a-5p
hsa-mir-23a-5p chr5_6947
chr17_16945 chr6_7381
hsa-mir-135b-5p hsa-mir-30a-3p
hsa-mir-224-5p hsa-mir-1
chr15_15541 hsa-mir-195-5p
hsa-mir-1246 chr12_13116
chr15_15204
chr15_15541_star
chr15_15204_star
chr1_1473_star
chr4_5063
hsa-mir-548d-3p
Abbreviation: mirna, microrna.
Figure 1 The results of deep sequencing of colorectal cancer mirnas.
Notes: Three types of tissues were derived from four different patients (1–4) (A). The symbol “+” indicates that samples were collected and “-” indicates that samples were 
not able to be collected. The distribution of upregulated mirnas and their overlapping expressions in different tissues are shown in (B). The distribution of downregulated 
mirnas and their overlapping expressions in different tissues are shown in (C).
Abbreviation: mirna, microrna.
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Figure 2 Verification results of upregulated miRNA.
Note: Figure shows the Ct value of every upregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.
Abbreviations: mirna, microrna; ct, cycle threshold; rnU6, cycle run six cycle.
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Figure 3 Verification results of downregulated miRNA.
Note: Figure shows the Ct value of every downregulated miRNA and its 95% confidence interval in normal mucosa, adenoma, and cancer tissues.
Abbreviations: mirna, microrna; ct, cycle threshold; rnU6, cycle run six cycle.
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Table 2 miRNA verification results
miRNA Average value X ± SD P-value
Mucosa Adenoma Cancer Mucosa/adenoma Mucosa/cancer Adenoma/cancer
Upregulated
mir-135b-5p 17.42±2.41 17.41±1.64 14.68±2.25 0.985 0.009 0.003
mir-183-5p 21.23±3.69 27.36±2.35 21.48±2.72 0.001 0.85 0.001
mir-96-5p 18.33±2.72 21.80±2.30 19.33±2.40 0.003 0.352 0.018
mir-18a-5p 16.59±1.99 18.48±1.68 14.23±1.59 0.02 0.004 0.001
mir-21-3p 24.99±2.52 17.03±3.96 16.90±5.40 0.001 0.001 0.949
mir-17-5p 21.25±7.10 17.68±4.14 12.00±2.58 0.119 0.005 0.001
mir-182-5p 23.51±3.91 25.12±3.16 19.04±2.74 0.28 0.004 0.001
mir-200a-5p 22.20±6.26 22.90±3.54 13.86±3.40 0.74 0.001 0.001
mir-200c-3p 23.90±4.74 21.42±3.83 13.63±3.63 0.172 0.001 0.001
Downregulated
mir-204-5p 12.60±5.15 16.73±3.75 16.35±4.94 0.035 0.083 0.833
mir-133a-3p 9.16±3.74 14.93±2.26 15.21±3.11 0.001 0.001 0.802
mir-145-5p 14.10±4.21 16.94±4.71 12.90±7.91 0.134 0.65 0.143
mir-145-3p 11.55±4.00 14.78±4.74 15.26±7.46 0.085 0.143 0.851
mir-1 19.53±4.56 19.40±3.19 21.40±4.72 0.934 0.335 0.236
mir-125b-5p 9.18±3.65 11.26±7.96 16.60±6.04 0.424 0.001 0.083
mir-139-5p 13.50±3.69 17.30±6.79 21.42±3.64 0.102 0.001 0.078
mir-100-5p 13.05±3.49 14.00±4.28 20.00±2.69 0.558 0.001 0.001
mir-30a-5p 11.80±2.82 12.16±4.46 17.65±2.94 0.729 0.001 0.002
Abbreviation: mirna, microrna.
colorectal cancer from Southeast China for studying the dif-
ferential expression patterns of miRNAs among samples of 
different cancer developmental stages. The objective was to 
determine a standard and valuable miRNA diagnostic index 
for the early detection of colorectal cancers in patients of 
Southeast China.
In this study, using deep sequencing, we detected two 
major types of miRNAs that are differentially expressed in 
different colorectal samples: 99 upregulated miRNAs and 
90 downregulated miRNAs in colorectal cancer, as well as 
70 upregulated and 27 downregulated miRNAs in adenoma 
tissues. The results were largely similar to previous reports2–7 
and confirmed the reliability of our experiments used for 
the analysis of distinct samples of Southeast China. Our 
data were also cross-validated by comparison between the 
deep-sequencing results and the qRT-PCR validation results. 
We further identified that miR-18a-5p and miR-21-3p were 
upregulated in both adenoma and cancer tissues, while miR-
133a-3p was downregulated in both adenoma and cancer 
tissues, which offers potential early miRNA indicators for 
colorectal cancer screening.
Research reported by Slattery et al8 found that overex-
pression of hsa-miR-18a-5p can reduce the risk of death 
from colorectal cancer. A systematic review reported by 
Clancy et al9 found that patients with colorectal cancers 
show upregulation of circulating hsa-miR-18a-5p, which 
may imply that hsa-miR-18a-5p can be used as a diagnostic 
marker. Calvano Filho et al10 also found that the expres-
sion of hsa-miR-18a-5p increases in breast cancer and 
this suggested a correlation may exist for other types of 
cancers.
Similarly, upregulation of miR-21-3p was found not only 
for colorectal cancer but also for a variety of cancers. Rotelli 
et al11 found that miR-21-3p was increased in the stools of 
patients with colorectal cancer and that it decreased after 
surgery, which suggests that it can be used as a prognostic 
factor for colorectal cancer. Other studies have found that 
miR-21-3p is associated with gynecological tumors and drug 
resistance.12 A few studies investigating whether it increases 
in colorectal cancer and colorectal adenoma have been 
conducted.12,13 Research reported by Doberstein et al14 found 
that miR-21-3p increased with tumorigenesis in a variety of 
tumors. In contrast, few studies have been conducted on the 
role of miR-133a-3p in the pathogenesis and development 
of colorectal cancer.15
In this research, differences in expression of miR-135b-5p, 
miR-17-5p, miR-182-5p, miR-200a-5p, and miR-200c-3p 
were statistically significant in comparisons between can-
cer and normal mucosa tissues, while no significance was 
observed for adenoma and normal mucosa tissues. The 
differences in miR-183-5p and miR-96-5p expression were 
statistically significant for adenoma and normal mucosa 
tissues and showed no significant differences in cancer and 
normal mucosa tissues.
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screening of mirnas for early diagnosis of colorectal cancer
In our miRNA deep-sequencing study, the expression 
patterns of miRNAs were similar in both adenoma and can-
cer tissues. This result might be due to several reasons. One 
explanation may be the small number of patients in this study, 
which requires further investigations either using larger 
sample numbers for the deep sequencing or more valida-
tions using larger patient samples. Our next step will be the 
verification of its value in more colorectal cancer samples. 
According to the literature, variations in miRNA detection 
were also associated with varying sources of patients with 
cancer. There may exist miRNA expression differences 
between different human races or humans with different 
environmental or diet habits. One of our research objectives is 
to identify such potential distinctions of miRNA expressions 
in different Chinese patient populations for a more precise 
medication. This study aimed to determine the links between 
miRNA biomarker variation and the occurrence of colorectal 
cancer in patients of Southeast China.16–22
In conclusion, this research found a number of important 
miRNAs that may have diagnostic and prognostic signifi-
cance in the occurrence and development of colorectal can-
cer. miR-18a-5p, miR-21-3p, and miR-133a-3p were found 
to be up- or downregulated in both adenoma and cancer 
tissues and can be used as early indicators of colorectal 
cancer during screening, while the increase or decrease 
of miR-135b-5p, miR-17-5p, miR-182-5p, miR-200a-5p, 
miR-200c-3p, miR-183-5p, and miR-96-5p in both cancer 
and adenoma tissues showed no obvious differences. Fur-
ther research is necessary for determining the appropriate 
screen index values that can be used for the diagnosis of 
colorectal cancer.
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